Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 9, 2007, Pages 1329-1335

  Kenney, Christopher ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Dopamine agonist; Parkinson's disease; Restless legs syndrome; Rotigotine; Transdermal

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; APOMORPHINE; CABERGOLINE; CARBIDOPA; CIMETIDINE; CYTOCHROME P450 INHIBITOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SILICONE; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADJUVANT THERAPY; APPLICATION SITE REACTION; ARTICLE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FIRST PASS EFFECT; FOOD; FOOD DRUG INTERACTION; HALLUCINATION; HUMAN; INSOMNIA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT COMPLIANCE; PRURITUS; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RESTLESS LEGS SYNDROME; SIDE EFFECT; SOMNOLENCE; SWEATING; SYMPTOM; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VISION; VOMITING; INTRADERMAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, CUTANEOUS; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; RESTLESS LEGS SYNDROME; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 34250821682     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.9.1329     Document Type: Article

References (42)

1. JANKOVIC J: Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. (2005) 20(Suppl. 11):S11-S16.
2. NUTT JG: Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa? Mov. Disord. (2007) 22(1):1-9.
3. DIAMOND A. JANKOVIC J: Treatment of advanced Parkinson's disease. Expert Rev. Neurother. (2006) 6(8):1181-1197.
4. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin. Neuropharmacol. (2000) 23(1):34-44.
5. RASCOL O, BROOKS DJ, KORCZYN AD et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. (2000) 342(20):1484-1491.
6. TINTNER R, JANKOVIC J: Dopamine agonists in Parkinson's disease. Expert Opin. Investig. Drugs (2003) 12(11):1803-1820.
7. JENNER P: A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology (2005) 65(2 Suppl. 1):S3-S5.
8. RUPNIAK NM, TYE SJ, JENNINGS CA et al.: Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology (1989) 39(3):329-335.
9. REYNOLDS NA, WELLINGTON K, EASTHOPE SE: Rotigotine: in Parkinson's disease. CNS Drugs (2005) 19(11):973-981.
10. NAIDU Y, CHAUDHURI KR: Thansdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. Expert Opin. Drug Deliv. (2007) 4(2):111-118.
11. HUTTON JT, METMAN LV, CHASE TN et al.: Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord. (2001) 16(3):459-463.
12. WATTS RL, JANKOVIC J, WATERS C et al.: Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology (2007) 68:272-276.
13. THE PARKINSON STUDY GROUP: A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol. (2003) 60(12):1721-1728.
14. QUINN N: Rotigotine Transdermal Delivery System (TDS) (SP-962): a multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and efficacy of rotigotine TDS in patients with advanced Parkinson' disease. Parkinsonism Relat. Disord. (2002) 7(Suppl. 1):S66.
15. LEWITT PA, LYONS KE, PAHWA R: Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology (2007) 68(16):1262-1267.
16. STIASNY-KOLSTER K, KOHNEN R, SCHOLUAAYER E, MOLLER JC, OERTEL WH: Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov. Disord. (2004) 19(12):1432-1438.
17. METMAN LV, GILLESPIE M, FARMER C et al.: Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin. Neuropharmacol. (2001) 24(3):163-169.
18. CALABRESE VP, LLOYD KA, BRANCAZIO P et al.: N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism. Mov. Disord. (1998) 13(5):768-774.
19. POEWE W, LUESSI F: Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology (2005) 65(2 Suppl. 1):S11-S14.
20. BELLUZZI JD, DOMINO EF, MAY JM, BANKIEWICZ KS, MCAFEE DA: N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov. Disord. (1994) 9(2):147-154.
21. VAN DER WEIDE J, DE VRIES JB, TEPPER PG, HORN AS: Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. Eur. J. Pharmacol.1 (1986) 125(2):273-282.
22. MORGAN JC, SETHI KD: Rotigotine for the treatment of Parkinson's disease. Expert Rev. Neurother. (2006) 6(9):1275-1282.
23. BERTAINA-ANGLADE V, LA ROCHELLE CD, BOYER PA, MOCAER E: Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav. Pharmacol. (2006) 17(8):703-713.
24. SCHELLER D, CHAN P, LI Q et al.: Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp. Neurol. (2007) 203(2):415-422.
25. SPLINTER MY: Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome (February). Ann. Pharmacother. (2007) 41(2):285-295.
26. CAWELLO W, BRAUN M, HORSTMANN R: Pharmacokinetics of transdermal dopaminergic stimulation in advanced Parkinson's disease. J. Clin. Pharmacol. (2005) 45:1091.
27. GULDENPFENNIG WM, POOLE KH, SOMMERVILLE KW, BOROOJERDI B: Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin. Neuropharmacol. (2005) 28(3):106-110.
28. BRAUN M, CAWELL0 W, POOLE K, HORTSMANN R: Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. 9th Congress of the European Federation of Neurological Societies. Athens, Greece (17-20 September 2005) P1245.
29. JANKOVIC J, WATTS R, MARTIN W, BOROOJERDI B: Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson's disease. Arch. Neurol. (2007) 64(5):676-682.
30. SWART PJ, OELEN WE, BRUINS AP, TEPPER PG, DE ZEEUW RA: Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry. J. Anal. Toxicol. (1994) 18(2):71-77.
31. HANSEN K, BRAUN M, HORSTMANN R: Low drug-drug interaction potential of rotigotine. J. Clin. Pharmacol. (2005) 45:1091.
32. GERDING TK, DRENTH BF, DE ZEEUW RA, TEPPER PG, HORN AS: Metabolism and disposition of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in conscious monkeys after subsequent i.v. oral, and ocular administration. Drug Metab. Dispos. (1990) 18(6):923-928.
33. BIANCHINE J, POOLE K, WOLTERING F: Efficacy and dose response of the novel transdermally applied dopamine agonist rorigotinc CDS in early Parkinson's disease.Neurology (2002) 58(Suppl. 3)A162-A163.
34. PARKINSON STUDY GROUP: Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA (2000) 294(15):1931-1938.
35. GILADI N, TOLOSA E, BOOTHMAN B: Rotigotine transdermal system in patients with idiopathic Parkinson's disease: results of two placebo- and comparator-controlled trials. World Parkinson Congress. Washington, D.C. (22-26 February 2006).
36. POEWE W, RASCOL O, QUINN N, GILADI N, BOOTHMAN B: Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. (2007) (In press).
37. PATTON J, NEILSON S, BOROOJERDI B: Tolerability of switching from an oral dopamine agonist to transdermal rotigotine in Parkinson's disease. First World Parkinson's Congress. Washington, D.C., USA (2006)
38. KORCZYN AD, REICHMANN H, BOROOJERDI B, HACK HJ: Rotigotine transdermal system for perioperative administration. J. Neural Transm. (2007) 114(2):219-221.
39. STIASNY-KOLSTER K, GARCIA-BORREGUERO D, SALETU B et al.: Rotigotine in the treatment of moderate to severe idiopathic restless legs syndrome-a double-blind placebo-controlled multi-center dose-finding study. 56th Annual Meeting of the American Academy of Neurology. San Francisco, USA (2005)
40. FRUCHT S, ROGERS JD, GREENE PE, GORDON MF, FAHN S: Fatting asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 52(9):1908-1910.
41. WEINTRAUB D, SIDEROWF AD, POTENZA MN et al.: Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch. Neurol. (2006) 63(7):969-973.
42. BABIC T, BOOTHMANN B, POLIVKA J et al.: Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clin. Neuropharmacol. (2006) 29(4):238-242.